SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Breast CANCEr Patients With Docetaxel and Cyclophosphamide
Status:
Completed
Trial end date:
2018-11-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of a single dose of SPI-2012 with
pegfilgrastim (Neulasta [NDC 55513-190-01] manufactured by Amgen) in patients with
early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the
Duration of Severe Neutropenia (DSN) in Cycle 1.